Alimera: Iluvien Marketing Authorization In Denmark For Diabetic Macular Edema

(RTTNews) - Alimera Sciences Inc (ALIM) said Thursday the Danish Health and Medicines Authority granted marketing authorization to Iluvien for the treatment of vision impairment associated with chronic diabetic macular edema considered insufficiently responsive to available therapies.

In addition to Denmark, Iluvien is now approved for marketing in Austria, France, Germany, Italy, Norway, Portugal, Spain and the United Kingdom, and is commercially available in the United Kingdom and Germany.

Iluvien is pending approval in eight countries including Belgium, Finland, Ireland, Poland and Sweden.

A new drug application for Iluvien is currently under review by the U.S. Food and Drug Administration.

Iluvien is a sustained release intravitreal implant used to treat vision impairment associated with chronic DME considered insufficiently responsive to available therapies.